Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) FCF Margin (2016 - 2025)

United Therapeutics (UTHR) has disclosed FCF Margin for 17 consecutive years, with 21.93% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 324345.0% to 21.93% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 32.7% through Dec 2025, down 1795.0% year-over-year, with the annual reading at 32.7% for FY2025, 486.0% down from the prior year.
  • FCF Margin hit 21.93% in Q4 2025 for United Therapeutics, down from 43.98% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 65.79% in Q1 2023 to a low of 4490.0% in Q4 2023.
  • Historically, FCF Margin has averaged 350.96% across 5 years, with a median of 35.91% in 2024.
  • Biggest five-year swings in FCF Margin: crashed -453334bps in 2023 and later soared 324345bps in 2025.
  • Year by year, FCF Margin stood at 53.25% in 2021, then dropped by -19bps to 43.34% in 2022, then tumbled by -10461bps to 4490.0% in 2023, then rose by 28bps to 3221.52% in 2024, then surged by 101bps to 21.93% in 2025.
  • Business Quant data shows FCF Margin for UTHR at 21.93% in Q4 2025, 43.98% in Q3 2025, and 16.22% in Q2 2025.